Oncology Times - OncTimes Talk Unknown

Asciminib May Be a Safer, More Effective Treatment for Patients With Newly Diagnosed Chronic Myeloid Leukemia

Chemotherapy Before and After Surgery Improved Outcomes for Patients With Resectable Locally Advanced Esophageal Adenocarcinoma

Trastuzumab Deruxtecan Delays Progression in HR+, HER2-low, and HER2 Ultralow Breast Cancer After Endocrine Therapy

Study Supports Osimertinib as Standard of Care for Patients With Locally Advanced EGFR-Mutated NSCLC

Study Finds Durvalumab Improved Progression-Free and Overall Survival in Limited Stage Small Cell Lung Cancer

German Study Finds New Regimen for Hodgkin Lymphoma More Effective, Less Toxic